Dimension Capital's $800M third fund shows science-AI boom
Dimension Capital has closed an $800 million third fund, underscoring how fast capital is flowing into startups that fuse biotech with software and AI compute. The New York firm's latest vehicle is 60% larger than its $500 million second fund from 18 months ago—proof that the dimension capital8217s 800m third raise tracks a booming science-compute thesis.
Key Takeaways
- Dimension Capital announced an $800 million third fund, about 60% larger than its $500 million second vehicle from 18 months earlier.
- The New York firm, founded in late 2022, invests at the intersection of science and compute.
- Portfolio highlights include Chai Discovery, New Limit, Modal Labs, and Anthropic shares via Coefficient Bio.
- Partners say their biotech-meets-software thesis has played out faster than expected.
Why does Dimension Capital's $800M raise matter now?
While many newer venture firms are still struggling to raise fresh capital, Dimension has been closing increasingly larger funds in quick succession. On Tuesday, the firm announced the $800 million vehicle—its third—signaling strong LP appetite for deep tech that straddles lab science and computing.
That growth matters because it shows investors are doubling down on AI-enabled biology and related infrastructure, even as fundraising remains tough for peers. More coverage of similar shifts sits in our Future Tech & AI Wonders hub.
Who built the firm behind this science-and-compute bet?
When Zavian Dar and Adam Goulburn—formerly partners at Lux Capital—teamed up with Obvious Ventures alum Nan Li to launch the firm four years ago, they bet founders would increasingly build companies crossing biotech and software. Dimension was founded in late 2022 and is based in New York.
The three partners now say they are impressed by how quickly that thesis has played out, according to TechCrunch's report.
Which portfolio wins show the thesis is working?
In 2024, Dimension co-led a $30 million seed investment in Chai Discovery, which is building open-source AI foundation models for drug development. Last week, Chai Discovery said it raised $400 million at a $3.8 billion valuation.
The firm also backed anti-aging startup New Limit at its Series A in January 2025. Earlier this month, New Limit—co-founded by Coinbase CEO Brian Armstrong—completed a Series C at a $3.1 billion valuation.
Other notable investments include inference company Modal Labs and Anthropic. Dimension received shares in Anthropic after the AI company acquired portfolio firm Coefficient Bio, a drug discovery platform, this spring for a reported $400 million.
What does an $800M third fund signal for deep tech?
The jump from a $500 million second fund to an $800 million third fund in roughly a year and a half suggests capital is concentrating around science-plus-compute startups. Dimension's path—from a late-2022 launch to successive larger vehicles—stands out against a tougher fundraising climate for many newer VCs.
For founders and LPs watching the space, the message is clear: the intersection of biology, software, and AI compute is attracting serious scale, and Dimension is raising to keep pace.